Business Wire

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

Share

Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields.

Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculoskeletal system. Rheumatology and dermatology therefore often overlap in diagnosing and managing diseases where the immune system plays a central role, and Indero will harness its expertise to deliver comprehensive, patient-focused solutions for these markets. The company’s full-service approach can support both early and late-phase trials across both specialties.

Dr Robert Bissonnette, Founder and Executive Chairman, commented: “As Innovaderm, we have served the dermatology clinical research community for 25 years, building a reputation for quality and excellence. As we move forward as Indero, we will continue to provide the expertise in dermatology that our clients have come to expect from us, while further strengthening our focus on rheumatology and expanding our support within this field. We are excited about the future and supporting the development of new therapies in these two areas of research, ultimately helping to improve patients' health and quality of life.”

Jeff Smith, CEO of Indero, added: “Our dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of rheumatology and dermatology conditions. The immune-mediated nature of both disease areas means that we are perfectly positioned to support clinical research across these specialties. Our network of investigators and research sites – combined with extensive in-house experience – means that we can support sponsors with the unique requirements of trials in these fields, from difficult-to-find patient populations to complex endpoints. As Indero, we are ‘all in’ with our commitment to providing sponsors with the rigorous scientific foundation and tailored expertise that their studies need.”

Visit www.inderocro.com to explore Indero’s services and expertise.

About Indero

Indero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery. Our full-service approach – which includes everything from protocol design and patient recruitment to trial monitoring and biometrics – provides biotech and pharmaceutical sponsors with the rigorous scientific foundation and tailored expertise their studies need to reach the finish line efficiently and effectively. With capabilities in the U.S., Canada, Europe, LATAM, and APAC; vast, continuously growing relationships with investigators and patients; and a dedicated research clinic through which we design and execute our own studies, Indero is the ideal partner for clinical needs at global scale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250307129954/en/

Contacts

For more information:
Valerie Coveney
Communications Specialist
Indero
vcoveney@inderocro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity17.3.2025 11:22:00 EET | Press release

Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging related illnesses, inflammaging, longevity and cancer prognosis. Oral consumption of AFO-202 strain of Aureobasidium pullulans produced Nichi BRITE and N-163 strain produced Neu REFIX together in pre-clinical and clinical studies having safely and beneficially modified NLR, are considered holding potential to help maintain astronauts health during space flight and also to bridge the gap between health span and life span by ‘Me-Byo’ phenomenon as published in Frontiers in Immunology while Neu REFIX standalone yielding enhanced dystrophin, an additional benefit that might help prevent muscle loss during space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316966059/en/ Astronauts during space missions, deep-sea researchers, high-altitude climbers, and workers exposed to radiation hazards, ar

Cineca to House Italy’s Most Powerful Quantum Computer IQM Radiance 5417.3.2025 11:04:00 EET | Press release

Italian supercomputing centre Cineca today announced an agreement with IQM Quantum Computers, a global leader in superconducting quantum computers, to deliver the most powerful quantum computer in Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317715500/en/ IQM Radiance 54-qubit superconducting quantum computer IQM Radiance quantum computer, powered by IQM’s 54-qubit quantum processing unit (QPU), will be installed in the fourth quarter of 2025. The quantum computer will be integrated into Leonardo, which is one of the world’s fastest supercomputers. This will mark a major technology and innovation milestone for Italy and the larger quantum ecosystem. The installation will also be the first on-premises quantum computer at Cineca, which further consolidates the institution’s position as a centre of excellence for scientific computing internationally and strengthens Italy’s position in quantum computing. IQM intends

Alipay+ Empowers New Growth Opportunities for Malaysian SMEs, Contributing More Than 80% of Inbound QR Payments via DuitNow17.3.2025 10:00:00 EET | Press release

In their first full year of partnership in 2024, Payments Network Malaysia Sdn Bhd (PayNet) and Ant International, a leading global digital payment, digitisation and financial technology provider, brought new economic opportunities to Malaysian SMEs, with Alipay+ making up more than 80 percent of cross-border inbound QR payments via DuitNow. In the peak travel season in December 2024, the partnership enabled 6 times growth in revenue for Malaysian merchants, compared to the same period in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317987292/en/ Malaysian SMEs can connect with global customers via DuitNow QR and Alipay+ In October 2023, Alipay+, a unified wallet gateway with cross-border payment and digitisation services under Ant International, went live on DuitNow QR, enabling Malaysian SMEs to accept QR payments from international travellers. Today, the number of Alipay+ payment partners that can make payment

NTT DATA and CrowdStrike Expand Partnership to Strengthen AI-Powered Cyber Resilience17.3.2025 10:00:00 EET | Press release

NTT DATA, a global digital business and IT services leader, and CrowdStrike, a global cybersecurity leader, today announced an expanded partnership to power NTT DATA's managed cybersecurity services with the AI-native CrowdStrike Falcon® cybersecurity platform. Cyberattacks are growing faster, stealthier and more sophisticated, while the cybersecurity skills gap leaves organizations vulnerable. To protect against modern threats, clients need AI-native platform technology and the benefits of a managed security solution to reduce complexity and serve as a force multiplier for security and IT teams. By combining NTT DATA’s world-class managed services with the power of the Falcon platform, clients gain the protection they need to stop breaches. Key capabilities of the partnership include: Integrated Managed Security Services: The integration of the Falcon platform with NTT DATA’s managed services provides organizations with advanced threat detection and response across their digital envir

Appaloosa Statement Regarding SES Announcement17.3.2025 10:00:00 EET | Press release

Appaloosa LP (“Appaloosa”), which manages funds holding a more than 7% economic interest in SES S.A. (“SES” or the “Company”), today issued the following statement in response to the SES Board of Directors’ (the “Board”) March 14, 2025 announcement. “The satellite industry is evolving rapidly and, as the SES Board’s announcement makes clear, even glacial change at SES requires strong shareholder advocacy. The initial steps the SES Board is taking to modernize its structure are long-overdue and only came following shareholder pressure. However, much more can, and must, be done -- with a greater sense of urgency than is evident from the Board’s incrementalism. “Specifically, adding a director with capital markets experience should be a priority as we believe such an appointment could prompt SES to finally begin addressing its underperforming capital investment practices and return value to shareholders. Likewise, the remaining board, capital structure and governance measures outlined in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye